PMID- 17525901
OWN - NLM
STAT- MEDLINE
DCOM- 20070830
LR  - 20220311
IS  - 0094-6176 (Print)
IS  - 0094-6176 (Linking)
VI  - 33
IP  - 4
DP  - 2007 Jun
TI  - Management of thromboembolism in hematologic malignancies.
PG  - 435-48
AB  - Patients with hematologic malignancies have increased risks of thromboembolism or 
      bleeding. The commonest thrombotic complication is venous thromboembolism (VTE). 
      Other thrombotic conditions occur in association with specific disorders, such as 
      thrombotic thrombocytopenic purpura in hematopoietic stem cell transplantation 
      and disseminated intravascular coagulation in acute promyelocytic leukemia. 
      Clinical trials show that unfractionated heparin (UFH) and low molecular weight 
      heparin (LMWH) are efficacious for VTE prophylaxis in cancer patients after major 
      surgery or when hospitalized for acute medical illnesses. These findings in 
      cancer patients are probably applicable to patients with hematologic 
      malignancies, in whom there are very few studies. However, the effectiveness of 
      anticoagulant VTE prophylaxis is not established in ambulatory patients with 
      cancer except for multiple myeloma patients treated with thalidomide and 
      chemotherapy. LMWH is widely used as initial treatment for VTE because it enables 
      home therapy without laboratory monitoring, thereby improving the patient's 
      quality of life. UFH is preferred in patients with high bleeding risks and renal 
      impairment. In cancer patients, vitamin K antagonists for the long-term treatment 
      of VTE are increasingly replaced by LMWH, which show superior efficacy. When 
      prescribing anticoagulant prophylaxis or treatment to patients with hematologic 
      malignancies, clinical benefits must be weighed carefully against the risks of 
      bleeding.
FAU - Chong, Beng H
AU  - Chong BH
AD  - Department of Haematology, St. George Hospital, Kogarah, New South Wales, 
      Australia. beng.chong@unsw.edu.au
FAU - Lee, Szu-Hee
AU  - Lee SH
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Semin Thromb Hemost
JT  - Seminars in thrombosis and hemostasis
JID - 0431155
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
SB  - IM
MH  - Anticoagulants/therapeutic use
MH  - Disease Management
MH  - Hematologic Neoplasms/*complications
MH  - Hemorrhage/etiology
MH  - Heparin, Low-Molecular-Weight/therapeutic use
MH  - Humans
MH  - Premedication
MH  - Risk Assessment
MH  - Thromboembolism/etiology/*therapy
RF  - 120
EDAT- 2007/05/26 09:00
MHDA- 2007/08/31 09:00
CRDT- 2007/05/26 09:00
PHST- 2007/05/26 09:00 [pubmed]
PHST- 2007/08/31 09:00 [medline]
PHST- 2007/05/26 09:00 [entrez]
AID - 10.1055/s-2007-976179 [doi]
PST - ppublish
SO  - Semin Thromb Hemost. 2007 Jun;33(4):435-48. doi: 10.1055/s-2007-976179.